Karyopharm says myelofibrosis sNDA submission remains on track for August
The company reported second-quarter 2026 results and flagged a September debt payment that could trigger default without new financing.
SEC filing
Latest
3 stories
Friday, September 25
Thursday, August 13
Friday, July 17
Karyopharm discloses 2026 cash retention program details for top executives
The board approved lump sum retention payments for four named executives on July 13, 2026, replacing previously guaranteed 2026 bonus amounts.
SEC filing